6-APB Stats & Data
FQDAMYLMQQKPRX-UHFFFAOYSA-NPharmacology
Metabolites
History & Culture
1993–2000
The benzofuran entactogens emerged from academic research into the structure-activity relationships of MDMA and related compounds. In 1993, medicinal chemist David E. Nichols and colleagues at Purdue University investigated 5-APDB and 6-APDB as serotonin releasing agents and entactogens, examining the role of the MDA dioxole ring structure in serotonergic neuron interactions.[cite:doi-10-1021-jm00075a027] This research was partly motivated by efforts to identify potential non-neurotoxic alternatives to MDMA, which was gaining recognition as a potentially useful adjunct in psychotherapy while simultaneously being linked to neurotoxic effects. Following this foundational work, 6-APB and its structural relative 5-APB were first described in the scientific literature in 2000 by Karin Briner and colleagues at Eli Lilly and Company in a patent application.[cite:url-patents-google-com-us7045545b1] At this time, the compounds were specifically studied as serotonin 5-HT2C receptor agonists for potential medical applications rather than as recreational substances.[cite:url-patents-google-com-us7045545b1]
2010–2014
Despite being characterized in the scientific literature a decade earlier, human recreational use of 6-APB was not documented until 2010, when the compound emerged for sale on the global research chemical market.[cite:doi-10-1007-s00213-020-05648-z] It became particularly prominent in the United Kingdom's "legal highs" market, where it was sold under the brand name "Benzofury" in distinctive bright orange packaging that became instantly recognizable.[cite:uk-ho-circular-008-2013] The compound's conspicuous branding attracted significant media attention during this period. 6-APB became one of the most frequently cited research chemicals in media coverage critical of legal highs, contributing to calls for regulatory action. This ultimately led to classification as a Temporary Class Drug in June 2013,[cite:uk-si-2013-1294] followed by permanent scheduling as a Class B substance alongside all other benzofuran entactogens in June 2014,[cite:url-legislation-gov-uk-made] effectively ending its presence in the legal market.
Effect Profile
Curated + 137 ReportsStrong visuals, auditory effects, and body load with moderate headspace
Strong empathy, euphoria, stimulation, and sensory enhancement
Strong stimulation, euphoria, focus, and anxiety/jitters
Empirical Duration
Erowid ReportsTolerance & Pharmacokinetics
drugs.wikiTolerance Decay
Acute tolerance: develops within a single session — the reset numbers above apply after sustained heavy use, not after one binge. Within-session tachyphylaxis usually resets largely overnight.
Within‑session tolerance is common and encourages redosing; spacing sessions by several weeks reduces cumulative serotonergic and potential 5‑HT2B‑mediated risks.
Cross-Tolerances
Demographics
Gender Distribution
Age Distribution
Reports Over Time
Effect Analysis
Erowid + BluelightEffects aggregated from 130 experience reports (80 Erowid + 57 Bluelight)
Effect Sentiment Distribution
Confidence Distribution
Positive Effects 48
Adverse Effects 52
Dose-Response Correlation
How effect frequency changes across dose levels
View data table
| Effect | Strong (n=17) | Heavy (n=21) |
|---|---|---|
| Euphoria | 76.5% | 85.7% |
| Music Enhancement | 76.5% | 61.9% |
| Visual Distortions | 52.9% | 76.2% |
| Empathy | 64.7% | 71.4% |
| Stimulation | 52.9% | 71.4% |
| Jaw Clenching | 58.8% | 42.9% |
| Color Enhancement | 52.9% | 42.9% |
| Tactile Enhancement | 47.1% | 38.1% |
| Sedation | 41.2% | 28.6% |
| Sweating | 41.2% | 28.6% |
| Nausea | 35.3% | 33.3% |
| Headache | 35.3% | 0% |
| Anxiety | 29.4% | 33.3% |
| Confusion | 29.4% | 33.3% |
| Auditory Effects | 29.4% | 23.8% |
Dose–Effect Mapping
Experience ReportsHow reported effects shift across dose tiers, based on 80 experience reports.
Limited tier coverage — most reports fall within the Strong / Heavy range. Effects at other dose levels may not be represented.
| Effect | Strong (n=17) | Heavy (n=21) | |
|---|---|---|---|
| euphoria | → | ||
| music enhancement | ↓ | ||
| visual distortions | ↑ | ||
| empathy | → | ||
| stimulation | ↑ | ||
| jaw clenching | ↓ | ||
| color enhancement | ↓ | ||
| tactile enhancement | ↓ | ||
| sedation | ↓ | ||
| sweating | ↓ | ||
| nausea | → | ||
| headache | — | → | |
| anxiety | → | ||
| confusion | → | ||
| auditory effects | ↓ | ||
| focus enhancement | ↓ | ||
| pupil dilation | ↑ | ||
| body high | → | ||
| muscle tension | — | → | |
| motor impairment | — | → |
Showing top 20 of 30 effects
Risk Escalation
Sentiment AnalysisAverage frequency of positive vs adverse effects across dose tiers
View effect breakdown
Adverse Effects
| Effect | Strong (n=17) | Heavy (n=21) | Change |
|---|---|---|---|
| Jaw Clenching | -27% | ||
| Sweating | -30% | ||
| Nausea | -5% | ||
| Headache | — | 0% | |
| Anxiety | +13% | ||
| Confusion | +13% | ||
| Pupil Dilation | +62% | ||
| Muscle Tension | — | 0% | |
| Motor Impairment | — | 0% | |
| Memory Suppression | — | 0% | |
| Increased Heart Rate | — | 0% | |
| Seizure | — | 0% |
Positive Effects
| Effect | Strong (n=17) | Heavy (n=21) | Change |
|---|---|---|---|
| Euphoria | +12% | ||
| Music Enhancement | -19% | ||
| Empathy | 10% | ||
| Stimulation | +34% | ||
| Color Enhancement | -18% | ||
| Tactile Enhancement | -19% | ||
| Focus Enhancement | -35% | ||
| Body High | 1% | ||
| Creativity Enhancement | +61% | ||
| Introspection | +21% |
Dosage Distribution
Dose distribution from experience reports
Form / Preparation
Most common forms and preparations reported
Body-Weight Dosing
Dose relative to body weight from reports with weight data
Redose Patterns
Redosing behavior across 65 reports
Harm Reduction
drugs.wiki- Onset is slow (often 60–120 min oral). Premature redosing is a leading cause of unexpectedly high total intake; wait at least 2 hours before considering any booster.
- Intranasal use is discouraged due to strong nasal irritation and variable absorption; oral is the safer, more predictable ROA.
- Salt form matters. By weight, pure 6‑APB succinate delivers about 72% of the active base compared with HCl; many commercial succinate batches contain substantial excess succinic acid, further lowering potency. Calibrate doses conservatively and test new batches.
- Product variability and mislabeling are common; recent Swiss and Dutch drug‑checking alerts continue to find 6‑APB in place of MDMA in pills and, in rare cases, mixtures or adulterants. Use reagent testing and, where available, lab‑based drug checking before consumption.
- Duration is longer than MDMA; plan dosing early in the day if sleep is needed the same night, and expect residual stimulation into the following day.
- Hydration and temperature: during dancing/heat, sip isotonic fluids (~300 mL/hour), take cool‑down breaks, and avoid overhydration; isotonic drinks reduce hyponatremia risk compared with plain water.
- Serotonin‑toxicity risk increases with MAOIs, SSRIs/SNRIs, tramadol/DXM, or other serotonergic releasers; avoid such combinations and seek urgent care if confusion, hyperthermia, rigidity, or clonus occur.
- 5‑HT2B receptor agonists (e.g., fenfluramine metabolite norfenfluramine) are linked to valvular heart disease with chronic exposure. Because benzofurans can activate 5‑HT2B in vitro, frequent or high‑dose 6‑APB use may plausibly elevate long‑term valvulopathy risk; spacing use and avoiding chronic patterns is prudent.
- Polydrug stimulant combinations (e.g., with amphetamine) amplify cardiovascular strain and should be avoided; if undertaken, significantly reduce doses and do not redose during the peak.
- Recent market reviews indicate 6‑APB continues to circulate as an NPS in parts of Europe; quality and composition vary year‑to‑year—further reason to test batches and titrate cautiously.
References
Data Sources
Cited References
- Iversen et al. (2013) - Neurochemical profiles of novel psychoactive substances
- Monte et al. (1993) - Synthesis and pharmacological examination of benzofuran analogs
- Pharmacological profile of benzofurans
- Psychopharmacology (2020) rat monoamine study
- Rickli et al. (2015) - Pharmacological profile of novel psychoactive benzofurans
- UNODC: I-TREND technical briefing on 6-APB
Additional references
- Erowid 6‑APB: Dosage & Effects/Durations
- Erowid 6‑APB: Effects page
- Saferparty.ch – 6‑APB substance page (Wirkung/Dauer/Dosierung/Mischkonsum)
- Saferparty.ch – MDMA pills found containing 6‑APB / mislabel examples
- Saferparty.ch – 6‑APB adulteration warning (example with heroin/caffeine)
- DrugWise factsheet – Benzo Fury (6‑APB/5‑APB) background
- StatPearls – Drug‑Induced Valvular Heart Disease (5‑HT2B agonists)
- DrugBank article – 5‑HT2B activation implicated in valvulopathy (fenfluramine/norfenfluramine)
- Bluelight – 6‑APB succinate vs HCl potency discussion
- Reddit – multiple vendor lab analyses and succinate dilution discussions